By
Drug Target Review2024-08-30T12:00:42
The nucleic acid drug, iSN04, could have applications for pathological angiogenesis involved in atherosclerosis, cancer, and retinopathy.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-05-11T12:59:00Z
2026-05-06T09:00:00Z
2026-05-05T13:24:00Z
Sponsored by HUB Organoids
2025-08-05T13:42:00
Sponsored by ICON plc., By Drug Target Review
2024-01-26T13:22:42
Sponsored by bit.bio
2023-07-04T10:05:58
Sponsored by Revvity
2026-05-05T13:24:00
Sponsored by HUB Organoids
2024-01-19T07:40:55
Sponsored by Euretos
Site powered by Webvision Cloud